Siegfried Holding AG Logo

Siegfried Holding AG

Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.

SFZN | SW

Overview

Corporate Details

ISIN(s):
CH0014284498 (+3 more)
LEI:
506700J9QD6IF3937W06
Country:
Switzerland
Address:
Untere Brühlstrasse 4, 4800 Zofingen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Siegfried Holding AG is a global Contract Development and Manufacturing Organization (CDMO) that partners with the pharmaceutical industry. With over 150 years of experience, the company operates as an integrated supplier, providing services across the entire value chain for both drug substances and finished drug products. Its core activities include chemical and analytical development, pilot manufacturing, scale-up, and commercial production of active pharmaceutical ingredients (APIs), intermediates, and various finished dosage forms like tablets, capsules, and sterile injectables. Siegfried leverages its global network of R&D and production sites to translate pharmaceutical innovations into industrial-scale manufacturing, producing medications for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 07:00
Board/Management Information
Siegfried announces Chief Financial Officer transition
English 18.6 KB
2025-09-29 06:30
Regulatory News Service
DINAMIQS opens cGMP manufacturing facility for viral vectors
English 20.5 KB
2025-09-29 02:00
Regulatory News Service
DINAMIQS opens cGMP manufacturing facility for viral vectors
English 16.6 KB
2025-09-26 06:30
Board/Management Information
Change in the Chairmanship of the Board of Directors
English 18.0 KB
2025-09-26 02:00
Board/Management Information
Change in the Chairmanship of the Board of Directors
English 14.1 KB
2025-09-11 02:00
Capital/Financing Update
Siegfried successfully places senior bonds of CHF 300 million
English 12.3 KB
2025-07-17 06:30
Board/Management Information
Change in Siegfried's Executive Committee
English 17.8 KB
2025-05-23 06:30
Regulatory News Service
Siegfried expands production capacity for ophthalmic drugs in El Masnou
English 18.6 KB
2025-05-23 02:00
Regulatory News Service
Siegfried expands production capacity for ophthalmic drugs in El Masnou
English 13.7 KB
2025-04-10 15:30
Post-Annual General Meeting Information
Siegfried shareholders approve all proposals at Annual General Meeting 2025
English 19.4 KB
2025-02-18 01:00
Earnings Release
Siegfried reports continued profitable growth fueled by strong underlying busin…
English 19.1 KB
2024-12-24 06:30
Environmental & Social Information
Siegfried once again confirmed in the Dow Jones Sustainability Index Europe
English 15.8 KB
2024-12-23 06:30
Environmental & Social Information
Siegfried once again confirmed in the Dow Jones Sustainability Index Europe
English 15.8 KB
2024-12-23 01:00
Environmental & Social Information
Siegfried once again confirmed in the Dow Jones Sustainability Index Europe
English 12.1 KB
2024-12-07 06:30
Board/Management Information
Changes in Siegfried's senior management team
English 17.7 KB

Automate Your Workflow. Get a real-time feed of all Siegfried Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Siegfried Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Siegfried Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-10-31 N/A Executive member Sell None 1,695,000.00 CHF
2024-10-31 N/A Executive member Sell None 1,584,260.00 CHF
2024-08-28 N/A Executive member Sell None 1,086,000.00 CHF
2024-08-28 N/A Executive member Sell None 380,100.00 CHF
2024-08-28 N/A Executive member Sell None 362,724.00 CHF
2024-06-14 N/A Non-Executive member Sell None 368,930.00 CHF
2024-03-06 N/A Executive member Sell None 4,587,500.00 CHF
2024-03-06 N/A Executive member Sell None 1,376,250.00 CHF
2024-03-06 N/A Executive member Sell None 917,500.00 CHF
2024-03-06 N/A Executive member Sell None 458,750.00 CHF

Peer Companies

Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.